Cancer Research Center Groningen (CRCG)

University of Groningen > Faculty of Medical Sciences > Cancer Research Center Groningen (CRCG)

Contact information

Ant. Deusinglaan 1
Building 3217 ('de Brug'), Room 7.21
9713 AV
Groningen
Netherlands
  • Phone: +31 50 363 4734

Organisational unit profile

Fundamental, Clinical and Translational Cancer Research.
The Cancer Research Center Groningen (CRCG) was established in 2012. The aim is to translate fundamental insights in oncogenesis and tumour behaviour from basic research into cancer prevention, improvement of early detection of cancer, and better treatment for cancer patients.

The mission of the CRCG is to clarify the molecular mechanisms that determine malignant transformation in a broad spectrum of tumors and to translate these fundamental insights into improved early detection and treatment of cancers. This will ultimately lead to personalized cancer therapy, thus reducing the unintended side effects of treatment on normal tissues and improving the quality of life of cancer survivors.

The CRCG was founded in 2012 as an independent research institute of the University Medical Center Groningen. Four key research programmes have been established:

  1. Damage and Repair in Cancer Development and Cancer Treatment (DARE);
  2. Guided Treatment in optimal Selected cancer patientsTranslational and Clinical research in Oncology (GUTS);
  3. Stem cells, Aging, Leukemia and Lymphoma (SALL);
  4. TARgeted Gynaecologic Oncology  (TARGON).


These programmes are supported by 60 PIs and 139 PhD or MD/PhD students who participate in the UMCG’s Graduate School of Medical Sciences (GSMS). The various programs are characterized by a strong interaction between basic and translational research programs, as shown by joint research meetings and projects.

Publications
  1. Never tear us a-PARP: Dealing with DNA lesions during mitosis

    Schoonen, P. M. & van Vugt, M. A. T. M. 2018 In : Molecular & Cellular Oncology. 5, 1, p. e1382670

    Research output: Scientific - peer-reviewArticle

  2. Role of germline aberrations affecting,andin gastric cancer susceptibility

    Weren, R. D. A., van der Post, R. S., Vogelaar, I. P., van Krieken, J. H., Spruijt, L., Lubinski, J., Jakubowska, A., Teodorczyk, U., Aalfs, C. M., van Hest, L. P., Oliveira, C., Kamping, E. J., Schackert, H. K., Ranzani, G. N., Gómez García, E. B., Hes, F. J., Holinski-Feder, E., Genuardi, M., Ausems, M. G. E. M., Sijmons, R. H., Wagner, A., van der Kolk, L. E., Cats, A., Bjørnevoll, I., Hoogerbrugge, N. & Ligtenberg, M. J. L. 12-Jan-2018 In : JOURNAL OF MEDICAL GENETICS. 7 p.

    Research output: Scientific - peer-reviewArticle

  3. Colorectal cancer incidence incarriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report

    Seppälä, T., Pylvänäinen, K., Evans, D. G., Järvinen, H., Renkonen-Sinisalo, L., Bernstein, I., Holinski-Feder, E., Sala, P., Lindblom, A., Macrae, F., Blanco, I., Sijmons, R., Jeffries, J., Vasen, H., Burn, J., Nakken, S., Hovig, E., Rødland, E. A., Tharmaratnam, K., de Vos Tot Nederveen Cappel, W. H., Hill, J., Wijnen, J., Jenkins, M., Genuardi, M., Green, K., Lalloo, F., Sunde, L., Mints, M., Bertario, L., Pineda, M., Navarro, M., Morak, M., Frayling, I. M., Plazzer, J-P., Sampson, J. R., Capella, G., Möslein, G., Mecklin, J-P., Møller, P. & Mallorca Group 2017 In : Hereditary cancer in clinical practice. 15, p. 18

    Research output: Scientific - peer-reviewArticle

  4. CHARACTERISTICS OF OVARIAN CANCER IN WOMEN WITH LYNCH SYNDROME

    Helder-Woolderink, J., de Bock, G., de Hullu, J., Hollema, H., Zweemer, R., Slangen, B., Gaarenstroom, K., van Beurden, M., van Doorn, L., Sijmons, R., Vasen, H. & Mourits, M. Nov-2017 In : International Journal of Gynecological Cancer. 27, p. 90-90 1 p.

    Research output: ScientificMeeting Abstract

View all (8,135) »

Prizes
  1. Karl Musshoff Prize

    Arjan Diepstra (Recipient), 24-Oct-2016

    Prize

  2. ERC consolidator grant

    Jan Schuringa (Recipient), 2012

    Prize: Fellowship awarded competitively

  3. NWO-VIDI

    Jan Schuringa (Recipient), 2009

    Prize: Fellowship awarded competitively

View all (12) »

Activities
  1. Junior Honours College

    Daemen, T. (Invited speaker)
    7-Jul-2016

    Activity: Talk or presentationInvited talk

  2. Cellular Metabolism in Disease: Friend or foe?

    Daemen, T. (Member of programme committee)
    20-Dec-2017

    Activity: ScientificParticipation in conference

  3. Masterclass VacTrain

    Daemen, T. (Invited speaker)
    9-May-201610-May-2016

    Activity: Talk or presentationInvited talk

View all (89) »

Press / Media
  1. Nieuwe ontwikkelingen in hematologie, MDS, AML, translationeel.

    Jan Schuringa

    22/11/2017

    1 media contribution

    Press / Media: Public Engagement Activities

  2. Experimentele hematologie verfijnt kijk op leukemie

    Jan Schuringa

    01/10/2017

    1 item of media coverage

    Press / Media: Public Engagement Activities

  3. Macrofagen herprogrammeren voor effectievere immuuntherapie

    Toos Daemen

    20/03/2017

    1 item of media coverage

    Press / Media: Public Engagement Activities

View all (31) »

View graph of relations

ID: 12296270